Antibody avidity following varicella-zoster virus infections.
The avidity of IgG antibodies following varicella-zoster virus (VZV) infections was investigated using urea treatment of antigen-bound serum antibody by indirect radioimmunoassay (RIA) and immunoblotting techniques. Sequential sera from 16 patients with varicella and 17 patients with zoster were tested, as well as sera from 80 seropositive individuals without a recent history of VZV disease. Both types of assay showed that low-avidity antibodies predominate early after primary infection, but that antibody avidity increases markedly during convalescence. Using RIA, all sera taken up to 12 weeks after the onset of varicella showed greater than 50% reduction in antibody titre after treatment with 8 M urea but thereafter the proportion of urea resistant antibody increased with time. In contrast, after recurrent infection, high avidity antibodies were found to predominate at all times. Only 6 of 47 sera tested from zoster cases showed greater than 30% reduction after urea treatment and all these were taken within 2 weeks after onset of rash. Immunoblotting also showed that the highly immunogenic p32/p36 nucleoproteins appear to induce predominantly low avidity antibodies, even after recurrent VZV infection. The results of this study indicate that treatment with 8 M urea in RIA for IgG antibodies may be a simple and reliable method for distinguishing primary and anamnestic antibody responses against VZV.
Kangro
H O
HO
Virology Department, St. Bartholomew's Hospital, London, England.
Manzoor
S
S
Harper
D R
DR
D000914:Antibodies, Viral / Q000276:immunology; D000915:Antibody Affinity; D002478:Cells, Cultured; D003289:Convalescence; D006562:Herpes Zoster / Q000276:immunology*; D014645:Herpesvirus 3, Human / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D011863:Radioimmunoassay; D012008:Recurrence; D014508:Urea / Q000494:pharmacology
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D014508:Urea